Topical doxorubicin hydrochloride therapy for carcinoma in situ of the bladder: a followup

J Urol. 1984 Jan;131(1):41-2. doi: 10.1016/s0022-5347(17)50186-x.

Abstract

A total of 10 patients with histologically proved carcinoma in situ of the bladder had remission of tumor after topical chemotherapy with doxorubicin hydrochloride for 24 months. Of the 10 patients 3 suffered new areas of carcinoma in situ 9 to 12 months after termination of intravesical chemotherapy. Furthermore, 1 of these 3 patients had a distal ureteral tumor. Fibrosis of the submucosal tissue was observed in every patient but a decrease in bladder capacity was observed in only 1 with prior radiotherapy.

MeSH terms

  • Administration, Topical
  • Adult
  • Aged
  • Carcinoma in Situ / drug therapy*
  • Carcinoma in Situ / pathology
  • Doxorubicin / administration & dosage*
  • Doxorubicin / adverse effects
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local
  • Urinary Bladder Neoplasms / drug therapy*
  • Urinary Bladder Neoplasms / pathology

Substances

  • Doxorubicin